Specific cytotoxic T lymphocytes in gene therapy

Journal of Molecular Medicine

Volumn 75, Issue 4, 1997, Pages 259-266

  Altenschmidt, Uwe ^a   Moritz, Dirk ^a   Groner, Bernd ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

Author keywords

primary T cells; recombinant T cell receptors; retroviral gene transfer vectors; transforming growth factor

Indexed keywords

T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; VIRUS VECTOR;

CYTOTOXIC T LYMPHOCYTE; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; ANTIBODIES, NEOPLASM; GENE THERAPY; IMMUNOTHERAPY, ADOPTIVE; MEMBRANE PROTEINS; MICE; NEOPLASMS, EXPERIMENTAL; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031006349     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050111     Document Type: Review

References (76)

1. Riddel SR, Greenberg PD (1995) Principles for adoptive T cell therapy in human viral diseases. Annu Rev Immunol 13: 545-586
2. Rosenberg SA (1991) Immunotherapy and gene therapy of cancer. Cancer Res [Suppl] 51:5074s-5079s
3. Brenner MB, Strominger JL, Krangel MS (1988) The gamma delta T cell receptor. Adv Immunol 43:133-192
4. Raulet DH (1989) The structure, function, and molecular genetics of the gamma delta T cell receptor. Annu Rev Immunol 7:175-207
5. Chang AE, Shu S (1992) Immunotherapy with sensitized lymphocytes. Cancer Invest 10:357-369
6. Mule JJ, Shu S, Schwartz SL et al (1984) Successful adoptive immunotherapy of established metastases with LAK and recombinant interleukin 2. Science 225:1487-1489
7. Rosenberg SA, Lotze MT, Muul LM et al (1987) A process report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer and interleukin-2 or high doses interleukin-2 alone. N Engl J Med 316:889-897
8. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang A, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT et al (1985) Observation on the systemic administration of autologous lymphocine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485-1492
9. Rosenberg SA, Spiess PJ, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321
10. Charkabarty NG, Sporn JR, Pasquale DR, Ergin MT, Mukherji B (1991) Suppression of lymphocine-activated killer cells generation by tumor-infiltrating lymphocytes. Clin Immunol Immunopath 59:407-416
11. Zinkernagel RM, Doherty PC (1974) Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic semiallogeneic system. Nature 248:701-702
12. Babbitt BP, Allen PM, Matsueda G, Haber E, Unanue ER (1985) Binding of immunogenic peptides to Ia histocompatibility molecules. Nature 317:359-361
13. Rammensee HG, Falk K, Rötzschke O (1993) MHC molecules as peptide receptors. Curr Opin Immunol 5:35-44
14. Germain RN (1994) MHC-dependent antigen procession and peptide presentation, providing ligands for T lymphocyte activation. Cell 76:287-299
15. Sadegh Nasseri S, Germain RN (1992) How MHC class II molecules work: peptide dependent competition of protein folding. Immunol Today 13:43-46
16. Neefjes JJ, Momburg F (1993) Cell biology of antigen presentation. Curr Opin Immunol 51:27-34
17. Doherty PC (1993) Cell mediated cytotoxicity. Cell 75:607-612
18. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydan N, McGlynn E, Livingston RB, Moe R, Cheever MA (1994) Existent T-cell antibody immunity to Her-2/neu protein in patients with breast cancer. Cancer Res 54:16-20
19. Tsomides TJ, Eisen HN (1994) T-cell antigen in cancer. Proc Natl Acad Sci USA 91:3487-3489
20. De Plaen E, Lurquin C, Van Pel A, Mariame B, Szikora J-P, Wölfel T, Sibille C, Chomez P, Boon T (1988) Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. Proc Natl Acad Sci USA 85:2274-2278
21. Lurquin C, Van Pel A, Mariame B, DePlaen E, Szikora J-P, Janssen C, Reddehase M Lejeune J, Boon T (1989) Structure of the gene coding for tum- transplantation antigen P91A. A peptide encoded by the mutated exon is recognized with Ld by cytolytic T cells. Cell 58:293-303
22. Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T (1991) The coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 173:1373-1384
23. Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Büschenfelde K-H, Beach D (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281-1284
24. + T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (GLY13-Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol Immunother 40:165-172
25. + T cells Proc Natl Acad Sci USA 91:3171-3175
26. Ioannides CG, Fisk B, Fan D, Biddison WE, Wharton JT, O'Brian CA (1993) Cytotoxic T cells isolated from ovarian malignant ascites recognized a peptide derived from the HER-2/neu proto-oncogen. Cell Immunol 151:225-234
27. Fisk B, Chesak B, Pollack MS, Wharton JZ, Ionnides CG (1994) Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro. Cell Immunol 157:415-427
28. Yoshino I, Peoples GE, Goedegebuure PS, Maziarz R, Eberlein TJ (1994) Association of HER-2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol 152:2393-2400
29. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER-2/neu-derived peptide. Proc Natl Acad Sci USA 92:432-436
30. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes an a human melanoma. Science 254:1643-1647
31. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora J-P, De Smet C, Brasseur F, van der Bruggen P Lethe B, Lurquin C et al (1994) Structure, chromosomal localization and expression of twelve genes on the MAGE family. Immunogenetics 40: 360-369
32. Boel P, Wildmann C, Sensi M-L, Brasseur R, Renauld J-C, Coulie P, Boon T, van der Bruggen P (1995) BAGE, a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167-175
33. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Bonn T (1995) A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes an a human melanoma. J Exp Med 182:689-698
34. Brasseur F, Marchand M, Vanwijck R, Herin M, Lethe B, Chomet P, Boon T (1992) Human gene MAGE-1, which codes for a tumor rejection antigen, is expressed by some breast tumors. Int J Cancer 52:839-841
35. Brasseur F, Rimoldi D, Lienard B, Lethe B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet A, Vacca A et al (1995) Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63:375-380
36. Weynants P, Lethe, B, Brasser F, Marchand M, Boon T (1994) Expression of MAGE genes by non-small-cell lung carcinomas. Int J Cancer 56:826-829
37. Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plean E, Lethe B, Coulie P, Boon T (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178:489-495
38. Coulie PG, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora J-P et al (1994) A new gene coding for a differentiaton antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 180:35-42
39. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA (1994) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 91:3515-3519
40. Bakker ABH, Schreurs MWJ, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG (1994) Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179:1005-1009
41. Cox AAL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716-719
42. Wang R-F, Robbins PF, Kawakami Y, Kang X-Q, Rosenberg SA (1995) Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 181:799-804
43. Zavada J, Zavadova Z, Pastorekova S, Ciampor F, Pastorek J, Zelnik V (1993) Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer 54: 268-274
44. Pastorek J, Pastorekova S, Callebaut I, Mornon JP, Zelnik V, Opavsky R, Zatovicova M, Liao S, Portelle D, Stanbridge EJ Zadava J, Burny A, Kettmann R (1994) Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 9:2877-2888
45. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J (1988) A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263:12820-12823
46. Barnd DL, Kerr LA, Metzgar RS, Finn OJ (1988) Human tumor-specific cytotoxic T cells generated from tumor-draining lymph node infiltrate. Transplant Res 20:339-341
47. Lancaster CA, Peat N, Duhig T, Wilson D, Taylor-Papadimitriou J, Gendler SJ (1990) Structure and expression of the human polymorphic epithelial mucin gene: an expressed VNTR unit. Biochem Biophys Res Commun 173:1019-1029
48. Jerome KR, Domenech N, Finn OJ (1993) Tumorspecific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognized EBV-immortalized B cells immortalized B cells transfected with polymorphic epithelial mucin cDNA. J Immunol 151:1654-1662
49. Berger MS, Locher GW, Sauer S, Gullick WJ, Waterfield MD, Groner B, Hynes NE (1988) Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48: 1238-1243
50. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
51. Peles E, Ben Levy; R, Tzahar E, Liu N, Wen D, Yarden Y (1993) Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with NEU/HER-2 suggests complex ligand-receptor relationships. Embo J 12:961-971
52. Kraus MH, Popescu NC, Amsbaugh SC, King CR (1987) Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. Embo J 6:605-610
53. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM (1993) Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255-263
54. Guerin M, Scheng ZM, Andrieu N, Riou G (1990) Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene 5:131-135
55. Weiss A, Littman DR (1994) Signal transduction by lymphocyte antigen receptors. Cell 76:263-274
56. Weidman E, Trueco M, Whiteside TL (1994) Relevance of the T cell receptor for immunotherapy of cancer. Cancer Immunol Immunother 39:1-14
57. Linsley PS, Ledbetter JA (1993) The role of CD 28 receptor during T cell responses to antigen. Annu Rev Immunol 11: 191-212
58. Jenkins MK, Johnson JG (1993) Molecules involved in T-cell costimulation. Curr Opin Immunol 5:361-367
59. + T cell-dependent surveillance. Cancer Res 50:3851-3858
60. + T cells to an antigen that no longer serve as a target. J Exp Med 178:933-940
61. Chen L, Lisley PS, Hellström KE (1993) Co-stimulation of T cells for tumor immunity. Immunol Today 14:483-485
62. Denfeld RW, Dietrich A, Wuttig C, Tanczos E, Weiss J, Vanscheidt W, Schöpf E, Simon JC (1995) In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell mediated anti-tumor immunity. Int J Cancer 62:259-265
63. Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chain consisting of antibody-binding domains and the γ and ζ subunits of the immunoglobulin and the T-cell receptors. Proc Natl Acad Sci USA 90:720-724
64. Moritz D, Wels W, Mattern J, Groner B (1994) Cytotoxic T lymphocytes with a grafted recognition specificity for erbB-2-expressing tumor cells. Proc Natl Acad Sci USA 91:4318-4322
65. Hwu P, Schafer GE, Treisman J, Schindler DG, Gross G, Cowherd R, Rosenberg SA, Eshhar Z (1993) Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor γ chain. J Exp Med 178:361-366
66. Irving BA, Weiss A (1991) The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64:891-901
67. Harwerth I-M, Weis W, Marte BM, Hynes NE (1992) Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J Biol Chem 267:15160-15167
68. Wels W, Beerli R, Hellmann P, Schmidt M, Marte BM, Kornilova ES, Hekele A, Mendelson J, Groner B, Hynes NE (1995) EGF receptor and p 185 erbB-e-specific single chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Im J Cancer 60:137-144
69. Moritz D, Groner B (1995) A spacer region between the single chain antibody- and the CD3 ζ-chain of chimeric T cell receptor components is required for efficient ligand binding and signalling activity. Gene Therapy 2:539-546
70. Evan GL, Lewis GK Ramsay G, Bishop JM (1985) Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol 5:3610-3616
71. Altenschmidt U, Kahl R, Moritz D, Schnierle BS, Gerstmayer B, Wels W, Groner B (1996) Cytolysis of tumor cells expressing the neu/erbB-2, erbB-4, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin Cancer Res 2:1001-1008
72. Romeo C, Seed B (1991) Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 64: 1037-1046
73. Wegener AM, Letourneur F, Hoeveler, A, Brocker T, Luton F, Malissen B (1992) The T cell receptor/CD3 complex is composed of at least two autocrine transduction modules. Cell 68: 83-95
74. Rünger TM, Klein CE, Becks JC, Bröcker EB (1994) The role of genetic instability, adhesion, cell motility and immune mechanisms in melanoma progression. Curr Opin Oncol 6:188-196
75. Boon T, (1992) Toward a genetic analysis of tumor rejection antigens. Adv Cancer Res 58:177-211
76. Altenschmidt U, Kahl R, Klundt E, Stöcklin E, Mihatsch M, Weindel K, Groner B (1996) Schwannoma cells induce a tumor cell specific cytotoxic T cell response upon transplantation in syngeneic rats, but escape elimination through the secretion of immunosuppressive factors. Int J Cancer (submitted)